Published in Curr HIV/AIDS Rep on September 01, 2014
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr (2006) 12.07
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology (2014) 3.14
Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis (2007) 3.02
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50
Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS (2005) 2.48
Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet (1998) 2.42
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos (2007) 2.17
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis (2006) 2.06
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis (2012) 1.91
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther (2011) 1.90
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr (2006) 1.86
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother (2009) 1.79
Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant (2007) 1.69
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant (2009) 1.65
Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res (2009) 1.64
HIV infection in older adults. Clin Geriatr Med (2007) 1.62
Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis (2009) 1.43
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos (2009) 1.41
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis (2003) 1.39
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother (2007) 1.37
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (2010) 1.30
Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos (2006) 1.26
Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother (2011) 1.25
Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol (2007) 1.21
The nephrotoxic effects of HAART. Nat Rev Nephrol (2009) 1.20
Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet (2011) 1.19
Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol (1998) 1.16
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med (2012) 1.15
Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther (2007) 1.14
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther (2013) 1.12
Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation (2005) 1.10
Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens (2008) 1.06
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother (2010) 1.06
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos (2009) 1.05
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother (2008) 1.03
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr (1999) 0.99
Drug uptake transporters in antiretroviral therapy. Pharmacol Ther (2011) 0.98
Warfarin-antiretroviral interactions. Ann Pharmacother (2009) 0.96
Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.95
Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet (2013) 0.95
The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr (2002) 0.95
Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs (2013) 0.94
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS (2010) 0.93
Drug transporters in HIV Therapy. Top HIV Med (2003) 0.92
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet (2007) 0.92
iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis (2010) 0.90
Telaprevir: pharmacokinetics and drug interactions. Antivir Ther (2012) 0.88
Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol (2011) 0.87
Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. AIDS Patient Care STDS (2012) 0.87
Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother (2014) 0.86
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol (2012) 0.86
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet (2004) 0.85
Kidney transplantation in HIV-positive adults: the UK experience. Int J STD AIDS (2013) 0.84
Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr (2013) 0.84
Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol (2011) 0.84
Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol (2014) 0.83
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit (2013) 0.82
Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr (2012) 0.81
Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol (2011) 0.81
Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta (2007) 0.81
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. AIDS Patient Care STDS (2011) 0.80
Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol (2007) 0.79
Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol (2007) 0.79
Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich) (2005) 0.79
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. Clin Infect Dis (2013) 0.79
Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. Ther Drug Monit (2014) 0.79
Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS (2008) 0.78
Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis (2006) 0.78
Lipid abnormalities. Clin Infect Dis (2003) 0.78
Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl (2002) 0.78
Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother (2012) 0.78
Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol (2011) 2.00
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97
An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr (2005) 1.89
Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy (2007) 1.88
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int (2012) 1.79
Buprenorphine use: the international experience. Clin Infect Dis (2006) 1.55
APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol (2011) 1.43
Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol (2008) 1.41
Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users. AIDS (2012) 1.41
Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS (2010) 1.37
Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr (2009) 1.34
Beyond surveillance: a role for respondent-driven sampling in implementation science. Am J Epidemiol (2013) 1.20
Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis (2006) 1.19
Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr (2006) 1.17
Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis (2008) 1.13
Mortality among injection drug users in Chennai, India (2005-2008). AIDS (2009) 1.09
Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol (2010) 1.07
Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs (2008) 1.06
Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol (2007) 1.03
Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection. Clin J Am Soc Nephrol (2009) 1.03
Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS (2006) 1.03
Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women. AIDS (2013) 1.01
Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis (2008) 1.01
Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndr (2008) 1.00
A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort. AIDS Patient Care STDS (2008) 1.00
High HIV prevalence and incidence among MSM across 12 cities in India. AIDS (2015) 0.99
Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation (2014) 0.98
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97
HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management. Expert Rev Anti Infect Ther (2008) 0.95
Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr (2011) 0.94
The impact of hepatitis C coinfection on kidney disease related to human immunodeficiency virus (HIV): a biopsy study. Medicine (Baltimore) (2011) 0.93
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation (2013) 0.92
Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis (2007) 0.91
Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy. Clin J Am Soc Nephrol (2013) 0.91
Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol (2014) 0.90
A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS (2014) 0.89
HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol (2010) 0.87
HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection. AIDS (2014) 0.85
Antiretroviral nephrotoxicities. Semin Nephrol (2008) 0.84
Does HIV infection promote early kidney injury in women? Antivir Ther (2013) 0.83
Patient-centered care for people living with multimorbidity. Curr Opin HIV AIDS (2014) 0.82
Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers. BMC Nephrol (2013) 0.79
Online CKD education for medical students, residents, and fellows: training in a new era. Adv Chronic Kidney Dis (2013) 0.79
The evolving science of apolipoprotein-L1 and kidney disease. Curr Opin Nephrol Hypertens (2016) 0.79
Buprenorphine in primary HIV care clinics: a big pill to swallow. Hopkins HIV Rep (2004) 0.79
Patterns of Kidney Function Before and After Orthotopic Liver Transplant: Associations With Length of Hospital Stay, Progression to End-Stage Renal Disease, and Mortality. Transplantation (2015) 0.78
Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs. BMC Infect Dis (2011) 0.78
Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens. AIDS (2016) 0.78
The impact of impaired kidney function and HIV infection on the risk of anemia. AIDS Res Hum Retroviruses (2012) 0.78
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr (2015) 0.77
Role of HIV-1 DNA levels as clinical marker of HIV-1-associated nephropathies. Nephrol Dial Transplant (2010) 0.77
Kidney function and mortality post-liver transplant in the Model for End-Stage Liver Disease era. Int J Nephrol Renovasc Dis (2011) 0.77
Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and ribavirin. Clin Nephrol (2013) 0.77
Impact of generic antiretroviral therapy (ART) and free ART programs on time to initiation of ART at a tertiary HIV care center in Chennai, India. AIDS Care (2012) 0.77
Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men. J Acquir Immune Defic Syndr (2016) 0.76
Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans. AIDS (2016) 0.75
Changes in Urinary Biomarkers over 10 Years is Associated with Viral Suppression in a Prospective Cohort of Women Living with HIV. J Acquir Immune Defic Syndr (2016) 0.75
Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected men. AIDS Res Hum Retroviruses (2013) 0.75
Kidney transplantation in HIV-infected patients. Am J Kidney Dis (2011) 0.75
Longitudinal Assessment of Proximal Tubular Dysfunction in HIV Seropositive and Seronegative Persons: Correlates and Implications. J Acquir Immune Defic Syndr (2017) 0.75
Glomerular filtration rate and proteinuria associations with coronary artery calcium among HIV-infected and HIV-uninfected men in the Multicenter AIDS Cohort Study. Coron Artery Dis (2017) 0.75
Injection drug network characteristics are important markers of HIV risk behavior and lack of viral suppression. J Acquir Immune Defic Syndr (2017) 0.75
A detailed analysis of methylmalonic acid kinetics during hemodialysis and after combined liver/kidney transplantation in a patient with mut (0) methylmalonic acidemia. J Inherit Metab Dis (2014) 0.75
Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag. Am J Hematol (2010) 0.75
Taking HAART to heart: antiretroviral toxicities. Hopkins HIV Rep (2003) 0.75
Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). New data on treatment-experienced patients and drug resistance. Hopkins HIV Rep (2007) 0.75
Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). The treatment of experienced patients and resistance mechanisms. Hopkins HIV Rep (2004) 0.75
3rd IAS conference: new drugs and treatment of experienced patients. Hopkins HIV Rep (2005) 0.75
Treatment of antiretroviral-experienced patients and immune-based therapy. Hopkins HIV Rep (2002) 0.75
Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections. HIV Clin Trials (2002) 0.75
HIV notes from the 40th annual meeting of the Infectious Diseases Society of America. Hopkins HIV Rep (2002) 0.75
Antiretroviral toxicities take center stage at the 9th CROI (Conference on Retroviruses and Opportunistic Infections). Hopkins HIV Rep (2002) 0.75
All wrapped up and nowhere to flow. Am J Med (2012) 0.75
HIV notes from the 39th Annual Meeting of the IDSA. Hopkins HIV Rep (2002) 0.75
Treatment of experienced patients and antiretroviral resistance issues from the 12th CROI. Hopkins HIV Rep (2005) 0.75
The tissue's the issue. Am J Med (2010) 0.75
Nursing and Health Care Preferences Among Opioid and Stimulant Using Black Sexual Minority Men: An Exploratory Study. J Assoc Nurses AIDS Care (2020) 0.75